These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32213632)

  • 1. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape.
    Martin CJ; Datta A; Littlefield C; Kalra A; Chapron C; Wawersik S; Dagbay KB; Brueckner CT; Nikiforov A; Danehy FT; Streich FC; Boston C; Simpson A; Jackson JW; Lin S; Danek N; Faucette RR; Raman P; Capili AD; Buckler A; Carven GJ; Schürpf T
    Sci Transl Med; 2020 Mar; 12(536):. PubMed ID: 32213632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors.
    Welsh BT; Faucette R; Bilic S; Martin CJ; Schürpf T; Chen D; Nicholls S; Lansita J; Kalra A
    Int J Toxicol; 2021; 40(3):226-241. PubMed ID: 33739172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8
    Li A; Chang Y; Song NJ; Wu X; Chung D; Riesenberg BP; Velegraki M; Giuliani GD; Das K; Okimoto T; Kwon H; Chakravarthy KB; Bolyard C; Wang Y; He K; Gatti-Mays M; Das J; Yang Y; Gewirth DT; Ma Q; Carbone D; Li Z
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.
    Canè S; Van Snick J; Uyttenhove C; Pilotte L; Van den Eynde BJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer.
    Gupta A; Budhu S; Fitzgerald K; Giese R; Michel AO; Holland A; Campesato LF; van Snick J; Uyttenhove C; Ritter G; Wolchok JD; Merghoub T
    Commun Biol; 2021 Nov; 4(1):1296. PubMed ID: 34789823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy.
    Jiang A; Qin Y; Springer TA
    Cancer Immunol Res; 2022 Apr; 10(4):453-467. PubMed ID: 35181792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.
    Mitra MS; Lancaster K; Adedeji AO; Palanisamy GS; Dave RA; Zhong F; Holdren MS; Turley SJ; Liang WC; Wu Y; Meng YG; Vernes JM; Schutten MM
    Toxicol Sci; 2020 May; 175(1):24-34. PubMed ID: 32077954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
    Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
    Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.
    Bernardo M; Tolstykh T; Zhang YA; Bangari DS; Cao H; Heyl KA; Lee JS; Malkova NV; Malley K; Marquez E; Pollard J; Qu H; Roberts E; Ryan S; Singh K; Sun F; Wang E; Bahjat K; Wiederschain D; Wagenaar TR
    Oncoimmunology; 2021 Mar; 10(1):1881268. PubMed ID: 33796402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer.
    Nilsson E; Doraiswamy V; Parrott JA; Skinner MK
    Mol Cell Endocrinol; 2001 Sep; 182(2):145-55. PubMed ID: 11514049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, and TGFbeta3) during embryonic rat testis development.
    Cupp AS; Kim G; Skinner MK
    Biol Reprod; 1999 Jun; 60(6):1304-13. PubMed ID: 10330085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms.
    Bedinger D; Lao L; Khan S; Lee S; Takeuchi T; Mirza AM
    MAbs; 2016; 8(2):389-404. PubMed ID: 26563652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
    Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of transforming growth factor beta production by nitric oxide-treated chondrocytes: implications for matrix synthesis.
    Studer RK; Georgescu HI; Miller LA; Evans CH
    Arthritis Rheum; 1999 Feb; 42(2):248-57. PubMed ID: 10025918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
    Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
    J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
    Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA
    Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.
    Formenti SC; Hawtin RE; Dixit N; Evensen E; Lee P; Goldberg JD; Li X; Vanpouille-Box C; Schaue D; McBride WH; Demaria S
    J Immunother Cancer; 2019 Jul; 7(1):177. PubMed ID: 31296256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
    Rodríguez-Ruiz ME; Rodríguez I; Mayorga L; Labiano T; Barbes B; Etxeberria I; Ponz-Sarvise M; Azpilikueta A; Bolaños E; Sanmamed MF; Berraondo P; Calvo FA; Barcelos-Hoff MH; Perez-Gracia JL; Melero I
    Mol Cancer Ther; 2019 Mar; 18(3):621-631. PubMed ID: 30683810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.